Minerva Neurosciences (NERV) 10-Q 6 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 05, 2014
Document Entity Information [Abstract]	'	'
Entity Registrant Name	'Minerva Neurosciences, Inc.	'
Entity Central Index Key	'0001598646	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	18,439,482
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets	'	'
Cash and cash equivalents	$23,639,558	$1,818,317
Prepaid expenses	583,539	852
Total current assets	24,223,097	1,819,169
Equipment, net	35,566	3,232
In-process research and development	34,200,000	19,000,000
Goodwill	14,869,399	7,918,387
Deferred public offering costs	'	433,998
Total assets	73,328,062	29,174,786
Current liabilities	'	'
Accounts payable	942,228	522,981
Accrued expenses and other current liabilities	850,424	815,239
Accrued collaborative expenses	1,386,493	'
Convertible promissory notes	'	58,270
Derivative liability	'	10,093
Total current liabilities	3,179,145	1,406,583
Deferred taxes	13,433,760	7,588,600
Total liabilities	16,612,905	8,995,183
Commitments and contingencies	'	'
Stockholders’ equity	'	'
Preferred stock; $.0001 par value; 100,000,000 shares authorized; none issued or outstanding as of September 30, 2014 and December 31, 2013, respectively	'	'
Common stock; $.0001 par value; 125,000,000 shares authorized; 18,439,482 and 6,112,738 shares issued and outstanding as of September 30, 2014 and December 31, 2013, respectively	1,844	611
Additional paid-in capital	124,002,381	38,008,783
Accumulated deficit	-67,289,068	-17,829,791
Total stockholders’ equity	56,715,157	20,179,603
Total liabilities and stockholders’ equity	$73,328,062	$29,174,786

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	18,439,482	6,112,738
Common stock, shares outstanding	18,439,482	6,112,738

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Expenses	'	'	'	'
Research and development	$24,737,835	$190,663	$39,939,958	$544,445
General and administrative	2,413,516	291,809	7,484,556	588,144
Total expenses	27,151,351	482,472	47,424,514	1,132,589
Loss from operations	-27,151,351	-482,472	-47,424,514	-1,132,589
Foreign exchange gains (losses)	10,989	-2,887	14,975	-2,887
Interest (expense) income	-14,835	-2,834	-2,049,738	'
Net loss	($27,155,197)	($488,193)	($49,459,277)	($1,135,476)
Net loss per share, basic and diluted	($1.53)	($0.12)	($4.58)	($0.29)
Weighted average shares outstanding, basic and diluted	17,752,371	4,091,027	10,798,432	3,858,687

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Stockholders' Equity (USD $)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance at Dec. 31, 2013	$20,179,603	$611	$38,008,783	($17,829,791)
Balance (in shares) at Dec. 31, 2013	'	6,112,738	'	'
Increase (Decrease) in Stockholders' Equity	'	'	'	'
Issuance of shares for business acquisition	16,541,834	148	16,541,686	'
Issuance of shares for business acquisition (in shares)	'	1,481,583	'	'
Issuance of common stock pursuant to an initial public offering and concurrent private placements, net of issuance costs	51,620,986	956	51,620,030	'
Issuance of common stock pursuant to an initial public offering and concurrent private placements, net of issuance costs (in shares)	'	9,566,557	'	'
Vesting of common shares issued	10,542,670	93	10,542,577	'
Vesting of common shares issued (in shares)	'	926,604	'	'
Stock-based compensation	5,177,341	'	5,177,341	'
Conversion of debt and interest to common stock	2,112,000	36	2,111,964	'
Conversion of debt and interest to common stock (in shares)	'	352,000	'	'
Net loss	-49,459,277	'	'	-49,459,277
Balances at Sep. 30, 2014	$56,715,157	$1,844	$124,002,381	($67,289,068)
Balance (in shares) at Sep. 30, 2014	'	18,439,482	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($49,459,277)	($1,135,476)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	29,879	'
Amortization of debt discount recorded as interest expense	1,952,309	'
Stock-based compensation expense	15,720,011	'
Unrealized foreign exchange gain	'	-2,626
Change in fair value of derivative	-10,093	'
Changes in operating assets and liabilities	'	'
Prepaid expenses	-539,761	7,125
Accounts payable	658,863	'
Accrued expenses and other liabilities	-682,549	180,919
Accrued collaborative expenses	1,386,493	'
Net cash used in operating activities	-30,944,125	-950,058
Cash flows from investing activities:	'	'
Cash acquired in business combination	1,167,869	'
Purchases of equipment	-33,739	'
Net cash provided by investing activities	1,134,130	'
Cash flows from financing activities:	'	'
Proceeds from working capital loans	1,882,817	'
Repayments of working capital loans	-1,882,817	'
Proceeds from sales of common stock in initial public offering	31,334,702	'
Proceeds from sales of common stock in private placements	23,706,118	1,850,000
Fees paid in connection with private placements	-280,000	'
Public offering costs paid	-3,129,584	'
Net cash provided by financing activities	51,631,236	1,850,000
Net increase in cash and cash equivalents	21,821,241	899,942
Cash and cash equivalents	'	'
Beginning of period	1,818,317	200,314
End of period	23,639,558	1,100,256
Supplemental disclosure of noncash investing and financing activities	'	'
Common stock issued as consideration for business acquisition	16,541,834	'
Plus liabilities assumed:	'	'
Accrued expenses and other	321,417	'
ProteoSys milestone payable	681,600	'
Deferred tax liability	5,970,560	'
Less assets acquired:	'	'
Prepaid expenses	42,926	'
Equipment	28,204	'
In-process research and development	15,200,000	'
Goodwill	7,076,412	'
Cash acquired in business merger	1,167,869	'
Incurred but unpaid public offering costs	10,250	'
Conversion of debt and interest to common stock	$2,112,000	'

Nature_of_Operations_and_Liqui

Nature of Operations and Liquidity	9 Months Ended
	Sep. 30, 2014
Nature Of Operations And Liquidity Disclosure [Abstract]	'
Nature of Operations and Liquidity	'
	NOTE 1 — NATURE OF OPERATIONS AND LIQUIDITY
	Nature of Operations
	Minerva Neurosciences, Inc. (“Minerva” or the “Company”), formerly known as Cyrenaic Pharmaceuticals Inc. (“Cyrenaic”) was incorporated on April 23, 2007. The Company is a biopharmaceutical company focused on the development of an experimental drug for the treatment of schizophrenia (discussed further in Note 6 — License Agreement). On November 12, 2013, Sonkei Pharmaceuticals, Inc. (“Sonkei”), a biopharmaceutical company focused on the development of an experimental drug for the treatment of depression and an affiliated company through certain common ownership, was merged into Cyrenaic with Cyrenaic being the surviving company. Subsequent to the merger, Cyrenaic changed its name to Minerva Neurosciences, Inc.
	On February 11, 2014, the Company acquired Mind-NRG (discussed further in Note 3 — Business Combinations).  Mind-NRG is a Swiss development stage biopharmaceutical company focused on the development and commercialization of an experimental drug for the treatment of Parkinson’s disease. The Company acquired 100% of the share capital of Mind-NRG largely to obtain the intellectual property estate which underpins Mind-NRG’s lead product candidate, renamed MIN-301.
	On February 12, 2014, subject to the completion of an initial public offering (“IPO”), the Company entered into a co-development and license agreement (discussed further in Note 8 — Co-Development and License Agreement) pursuant to which the licensor granted the Company an exclusive license, in certain territories, under certain patent and patent applications to sell products containing any orexin 2 compound, controlled by the licensor and claimed in a licensor patent right, as an active ingredient, or MIN-202, for any use in humans. The license became effective on July 7, 2014 at the closing of the IPO and the payment of the $22.0 million license fee was made at that date.
	Going Concern
	The Company has limited capital resources and has incurred recurring operating losses and negative cash flows from operations since inception. As of September 30, 2014, the Company has an accumulated deficit of approximately $67.3 million. Management expects to continue to incur operating losses and negative cash flows from operations. The Company has financed its business to date from proceeds from the sale of common stock, loans and convertible promissory notes. On July 7, 2014, the Company completed an IPO and received net proceeds of $28.2 million, including the over allotment. In addition, on July 7, 2014, the Company sold shares of its common stock in two private placements resulting in net proceeds to the Company of approximately $23.4 million.
	The Company will need to raise additional capital in order to continue to fund operations and fully fund its clinical development programs. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company.  If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued.
	The accompanying condensed consolidated financial statements have been prepared as though the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES
	Basis of presentation
	The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the financial position as of September 30, 2014 and the results of operations for the three and nine months ended September 30, 2014 and 2013 and cash flows for the nine months ended September 30, 2014 and 2013. The results of operations for the three and nine months ended September 30, 2014, are not necessarily indicative of the results to be expected for the full year. When preparing financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
	Actual results could differ from those estimates. The balance sheet as of December 31, 2013 was derived from the audited financial statements. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited financial statements for the years ended December 31, 2013 and 2012.
	From its inception the Company has devoted substantially all of its efforts to business planning, engaging regulatory, manufacturing and other technical consultants, planning and executing clinical trials and raising capital.
	Consolidation
	The accompanying consolidated financial statements include the results of the Company and its wholly-owned subsidiary, Mind-NRG. Intercompany transactions have been eliminated.
	Significant risks and uncertainties
	The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of and demand for Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.
	The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.
	Use of estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
	Prior to the completion of the Company’s IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The board of directors determined the estimated fair value of the Company’s common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event, such as an IPO of common stock or a sale of the Company. The Company utilized various valuation methodologies in accordance with the framework of the 2013 American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. The methodologies included a probability-weighted expected return methodology that determined an estimated value under an IPO scenario and a sale scenario based upon an assessment of the probability of occurrence of each scenario. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates include assumptions regarding future performance, including the successful completion of preclinical studies and clinical trials and the time to complete an IPO or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.
	Research and development costs
	Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company. We determine our expenses related to clinical studies based on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual accordingly. The expenses for some trials may be recognized on a straight-line basis if the expected costs are expected to be incurred ratably during the period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued expenses.
	In July 2014, the Company paid a $22.0 million license fee, which has been included as a component of research and development expense since the licensed rights were not deemed to have an alternative future use. The Company accounts for the co-development and license agreement pursuant to which the license fee was paid as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Costs between the Company and the licensor with respect to each party’s share of development costs that have been incurred pursuant to the joint development plan are recorded within research and development expense or general and administrative expense, as applicable, in the accompanying condensed consolidated financial statements due to the joint risk-sharing nature of the activities. The Company has included $1.4 million in accrued expenses as of September 30, 2014 related to this agreement.
	In-process research and development (“IPR&D”) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the balance sheet, rather than expensed, regardless of whether these assets have an alternative future use.
	The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing, until completion or abandonment of research and development efforts associated with the project. An IPR&D asset is considered abandoned when it ceases to be used (that is, research and development efforts associated with the asset have ceased, and there are no plans to sell or license the asset or derive defensive value from the asset). At that point, the asset is considered to be disposed of and is written off. Upon successful completion of each project, the Company will make a determination about the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, IPR&D assets, for impairment annually on November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. When testing indefinite-lived intangibles for impairment, the Company may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the asset is impaired. Alternatively, the Company may bypass this qualitative assessment for some or all of its indefinite-lived intangibles and perform the quantitative impairment test that compares the fair value of the indefinite- lived intangible asset with the asset’s carrying amount.
	Stock-based compensation
	The Company recognizes compensation cost relating to share-based payment transactions in operating results using a fair-value measurement method, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Series Codification (“ASC”) -718 Compensation-Stock Compensation. ASC-718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in operating results as compensation expense over the requisite service period of the awards based on fair value of the granted instruments. The Company determines the fair value of share-based awards using the Black-Scholes option pricing model, which uses both historical and current market data to estimate fair value. This model incorporates various assumptions such as the risk-free interest rate, the expected volatility of the Company’s stock price, the stock’s expected dividend yield and the expected life of the options. The Company reduces the amount of compensation expense it recognizes for the expected amount of pre-vesting forfeitures.
	Grants to non-employees are accounted for in accordance with ASC-505-50 Equity — Based Payments to Non-Employees. The fair value of the instruments awarded are remeasured until the earlier of the date at which a commitment for performance by the counterparty to earn the equity instrument is reached or the date at which the counterparty’s performance is complete. The Company determines the fair value of share-based awards granted to non-employees using the Black-Scholes option pricing model.
	Loss per share
	Basic loss per share excludes dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity.
	Income taxes
	The Company utilizes the liability method of accounting for income taxes as required by ASC Topic 740 Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criterion in determining if a valuation allowance should be provided. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	ASC Topic 740 also covers the accounting for uncertainty in income taxes recognized in the consolidated financial statements. The guidance prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. ASC Topic 740 provides guidance on the recognition of interest and penalties related to income taxes. There were no interest or penalties related to income taxes for the three and nine months ended September 30, 2014 and 2013. The Company has elected to treat interest and penalties, to the extent they arise, as a component of income taxes. Income tax years beginning in 2011 for federal and state purposes are generally subject to examination by taxing authorities, although net operating losses from all prior years are subject to examinations and adjustments for at least three years following the year in which the tax attributes are utilized.
	Deferred public offering costs
	Deferred public offering costs include certain legal, accounting and other costs directly attributable to the Company’s public offering of common stock. Upon completion of the Company’s IPO on July 7, 2014, these amounts were offset against the proceeds of the offering.
	Business combinations
	For business combinations the Company utilizes the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. These standards require that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based their respective fair values at the date of acquisition. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred. The Company recognizes separately from goodwill the fair value of assets acquired and the liabilities assumed. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the acquisition date fair values of the assets acquired and liabilities assumed. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the Company’s estimates are subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may retroactively record adjustments to the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statements of operations.
	Goodwill
	The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The Company tests its goodwill for impairment annually at November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. There was no impairment of goodwill for the year ended December 31, 2013 and the Company believes there was no impairment for the three and nine months ended September 30, 2014.
	Convertible promissory notes
	The Company had issued 8% convertible promissory notes consisting of (i) $1.3 million face value convertible promissory notes and(ii) €518,519 face value convertible promissory notes. The Euro denominated notes were acquired in conjunction with the merger with Sonkei (discussed further in Note 3 — Business Combinations), and recorded at their fair value of approximately $0.7 million on the date of the merger.
	In conjunction with the IPO, the Company’s 8% convertible promissory notes in the face amount of $1.3 million and €518,519 including $0.1 million in accrued interest, were converted on July 7, 2014 at the IPO price of $6.00 per share into 352,000 shares of the Company’s common stock. There were no debt instruments outstanding on September 30, 2014.
	Discount Purchase Option
	The Company’s 8% convertible promissory notes contain an embedded derivative related to the conversion option containing a discount purchase feature in a qualified financing, as defined in such convertible promissory notes. The derivative was carried at fair value and was classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs. As of December 31, 2013, the fair value of the derivative liability was determined to be $10,093 using a probability-weighted valuation model applying the following assumptions: (i) discount rate of 8.0%, (ii) remaining term of approximately 6 months and (iii) the probabilities of conversion under various circumstances as at the date of measurement. The fair value of the derivative liability was remeasured at the July 7, 2014 conversion date and the fair value of the liability was determined to be $0. The $10,093 decrease in the fair value of the derivative liability was included as a component of interest for the nine months ended September 30, 2014. No amounts were charged to interest during the three months ended September 30, 2014.
	$3.50/€3.50 Conversion Option
	The Company’s 8% convertible promissory notes contained an embedded derivative related to the beneficial conversion feature of the notes. The initial fair value of the derivative liability at the date of issuance in November 2013 was determined by measuring the difference between the conversion price and the fair value of common stock at the commitment date. The Company recorded a debt discount for the fair value of the derivative, which was limited to the proceeds received of approximately $2.0 million, with an offsetting increase to additional paid-in capital. The beneficial conversion charge was included in the balance sheet at December 31, 2013 as a discount to the related convertible promissory notes. The discount was accreted as non-cash interest expense over the term of the debt using the effective interest method. The debt was converted into common stock in conjunction with the Company’s IPO on July 7, 2014 and the Company recognized approximately $0 and $2.0 million in non-cash interest expense within interest expense (income), net during the three and nine month periods ended September 30, 2014, respectively.
	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by FASB and are adopted by the Company as of the specified effective date. The Company believes that the impact of other recently issued but not yet adopted accounting pronouncements will not have a material impact on the financial position, results of operations, and cash flows, or do not apply to the Company’s operations.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915) which eliminates the definition of a development stage entity and removes the financial reporting distinction between development stage entities and other reporting entities under GAAP.  The Company early adopted this standard and thus has eliminated its historical inception to date information in the financial statements.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40) which provides guidance on disclosure requirements when there is substantial doubt about an entity’s ability to continue as a going concern. The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter, with early adoption permitted. The Company will evaluate this amendment but does not believe that it will have a material impact on its financial position, results of operations or cash flows.

Business_Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Business Combinations	'
	NOTE 3 — BUSINESS COMBINATIONS
	Mind-NRG
	On February 11, 2014, the Company acquired Mind-NRG, a Swiss development stage biopharmaceutical company focused on the development and commercialization of an experimental drug for the treatment of Parkinson’s disease. This transaction was accounted for as a business combination by the Company. The purchase price consists of 1,481,583 shares of the Company’s common stock (which includes 148,160 shares held in escrow until the expiration of the holdback period, February 11, 2015) with an estimated fair value of $11.17 per share, or approximately $16.5 million. The Company acquired 100% of the share capital of Mind-NRG largely to obtain the intellectual property estate that underpins Mind-NRG’s lead product candidate, recently renamed MIN-301.
	The fair value of the Company’s common stock issued was determined based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event, such as an IPO or a sale of the Company. The purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Mind-NRG. The final purchase price may be adjusted up to one year from the date of the merger. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.
	·	The fair value of current assets and liabilities approximated their book value.
	·	The Company measured the value of the acquired IPR&D using the income approach — multi period excess earnings method and assembled workforce using the cost approach (for contributory asset charge calculations). The multi-period excess earning method measures the present value of the future earnings expected to be generated during the remaining lives of the subject assets.
	·	The Company recorded a deferred tax liability for the difference in the book and tax basis of the IPR&D, multiplied by the effective income tax rate.
	The establishment of the fair value of the consideration for an acquisition, and the allocation to identifiable tangible and intangible assets and liabilities requires the extensive use of accounting estimates and management judgment. The fair values assigned to the assets acquired and liabilities assumed are from estimates and assumptions based on data currently available.
	The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. The goodwill recorded recognizes the value of the overall development program, both the current pre-clinical development program in process and the future clinical trial development strategy. Such goodwill is not deductible for tax purposes. The aggregate consideration of $16.5 million has been allocated to assets acquired and liabilities assumed based on estimated fair values at the February 11, 2014 as follows:
	Cash	$	1,167,869
	Other assets		71,130
	Goodwill		7,076,412
	In-process research and development		15,200,000
	Deferred tax liability		(5,970,560	)
	Accrued expenses		(321,417	)
	ProteoSys milestone payable		(681,600	)
		$	16,541,834
	IPR&D, an indefinite-lived asset, will be included as an asset on the Company’s balance sheet until such time that: (i) a marketing approval to commercially sell the drug is received from a regulatory agency, in which case it will be amortized over its expected commercial life, or (ii) such time as the IPR&D is deemed to be impaired, in which case it will be expensed. The transaction is being treated as a stock purchase for income tax purposes and accordingly, the tax bases of Mind-NRG’s assets and liabilities are not adjusted for the effect of purchase accounting. A deferred tax liability of $6.0 million has been recorded for the difference in the book and tax basis of the IPR&D, multiplied by the effective income tax. As of September 30, 2014, the Company corrected the deferred tax rate used to record a deferred tax liability at the acquisition date by recording a $0.1 million reduction to deferred tax liability with a corresponding reduction to goodwill.
	Sonkei
	On November 12, 2013, Cyrenaic was merged with Sonkei, with Cyrenaic being the survivor company. Each share of Sonkei common stock was converted into 0.383 shares of Cyrenaic common stock, resulting in the issuance of 2,423,368 shares. There were certain common stockholders between Sonkei and Cyrenaic however, since the underlying investors in the venture funds were not “substantially similar”, the merger was accounted for a business combination with Cyrenaic being treated as the acquirer. The results of Sonkei are included in the consolidated financial statements commencing November 12, 2013. The Company merged with Sonkei in order to acquire Sonkei’s lead product candidate, MIN-117.
	At the date of the merger, a Sonkei non-employee held 1,112,500 shares of Sonkei common stock with a nonrecourse note due to Sonkei, which was being treated as a stock option for accounting purposes. In connection with the merger, the Company issued 426,176 shares to the holder with a nonrecourse note (discussed further in Note 9 — Stockholders’ Equity) in order to replace the holder’s stock options in Sonkei. Due to the nonrecourse note, these shares of the Company were treated as stock options for accounting purposes and the holder of the option can only vest in the stock options if the holder continues to provide services to the Company through the time of a change in control, as defined. In summary, the Company issued replacement stock options of the Company for the old Sonkei stock options. As a change in control was not deemed probable as of the merger date, the options have not been included as part of the consideration transferred in the merger accounting. Accordingly, the Company will recognize all of the compensation expense for these stock options in the consolidated statement of operations once achievement of the performance condition becomes probable (see Note 9 — Stockholders’ Equity). The merger accounting purchase price was therefore determined based upon the common stock shares issued of 1,997,192 at a valuation of $9.49 per common share for a total purchase price of approximately $18.9 million.
	The fair value of the Company’s common stock issued was determined based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event, such as an IPO or a sale of the Company. The purchase price allocation was based upon an analysis of the fair value of the assets and liabilities acquired from Sonkei. Identifying the fair value of the tangible and intangible assets and liabilities acquired required the use of estimates by management, and were based upon currently available data, as noted below.
	·	The fair value of current assets and liabilities approximated their book value.
	·	The fair value of the convertible promissory notes was determined based upon a number of factors including (i) interest rate, (ii) creditworthiness of the Company, (iii) the applicable foreign exchange rate and (iv) the conversion features (described in Note 7 — Debt). The face amount of the note acquired is €518,519 (approximately $0.7 million at November 12, 2013).
	·	The Company measured the value of the acquired IPR&D using the income approach — multi period excess earnings method and assembled workforce using the cost approach (for contributory asset charge calculations). The multi-period excess earning method measures the present value of the future earnings expected to be generated during the remaining lives of the subject assets.
	·	The Company recorded a deferred tax liability for the difference in the book and tax basis of the IPR&D, multiplied by the effective income tax rate.
	The Company allocated the excess of purchase price over the identifiable intangible and net tangible assets to goodwill. The goodwill recorded recognizes the synergies and value of the overall combined development programs, both the current pre-clinical development program in process and the future clinical trial development strategy. Such goodwill is not deductible for tax purposes. The aggregate consideration of $18.9 million has been allocated to assets acquired and liabilities assumed based on estimated fair values at the date of merger November 12, 2013 as follows:
	Cash	$	631,478
	Goodwill		7,792,987
	In-process research and development		19,000,000
	Accrued expenses		(334,423	)
	Derivative liability		(3,476	)
	Deferred taxes		(7,463,200	)
	Convertible promissory notes (see Note 7)		(680,000	)
		$	18,943,366
	The IPR&D, an indefinite-lived asset, will be included as an asset on the Company’s consolidated balance sheet until such time that: (i) a marketing approval to commercially sell the drug is received from a regulatory agency, in which case it will be amortized over its expected commercial life, or (ii) such time as the IPR&D is deemed to be impaired, in which case it will be expensed. The transaction is being treated as a stock purchase for income tax purposes and accordingly, the tax bases of Sonkei’s assets and liabilities are not adjusted for the effect of purchase accounting. A deferred tax liability of $7.5 million has been recorded for the difference in the book and tax basis of the IPR&D, multiplied by the effective income tax. The acquired net operating losses of Sonkei of approximately $5.3 million had a full valuation allowance, however, will be not limited under Internal Revenue Code Section 382 as the amount that could be utilized after limitation exceeds the amount of the net operating loss carryforward. As of September 30, 2014, the Company corrected the deferred tax rate used to record a deferred tax liability at the acquisition date by recording a $0.1 million reduction to deferred tax liability with a corresponding reduction to goodwill.
	The unaudited financial information in the table below summarizes the combined results of operations for the Company, Sonkei and Mind-NRG on a pro forma basis as though the companies had been combined as of January 1, 2013. The unaudited pro forma financial information for the three and nine months ended September 30, 2014 and 2013 combines the Company’s historical results for these years with the historical results for the comparable reporting periods for Sonkei and Mind-NRG. The unaudited pro forma financial information below is for informational purposes only and is not indicative of the results of operations or financial condition that would have been achieved if the merger would have taken place at the beginning of each of the periods presented and should not be taken as indicative of the Company’s future results of operations or financial condition. Included in our results of operations for the nine months ended September 30, 2014 is $1.3 million in operating expenses attributable to Mind-NRG.
		Three Months Ended						Nine months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Operating loss	$	(27,155,197	)	$	(1,110,023	)	$	(49,912,152	)	$	(2,682,000	)
	Loss per share	$	(1.53	)	$	(0.15	)	$	(4.53	)	$	(0.37	)

Accrued_Expenses_and_Other_Lia

Accrued Expenses and Other Liabilities	9 Months Ended
	Sep. 30, 2014
Payables And Accruals [Abstract]	'
Accrued Expenses and Other Liabilities	'
	NOTE 4 — ACCRUED EXPENSES AND OTHER LIABILITIES
	Accrued expenses and other liabilities consist of the following:
		September 30, 2014		December 31, 2013
	Accrued payroll	$	229,785	$	126,910
	Accrued excise and franchise taxes		203,991		—
	Research and development costs		168,640		58,117
	Primomed research funding (1)		132,721		—
	Professional fees (2)		70,445		595,215
	Consulting and other costs		27,024		5,031
	Vacation pay		17,818		5,690
	Interest payable		—		24,276
		$	850,424	$	815,239
	-1	Under the terms of a research agreement with Primomed, the Company received grant funds that will be used to offset certain costs under the MIN-301 development program.
	-2	Accounts payable and accrued professional fees at December 31, 2013 included $0.4 million that was incurred in connection with the preparation for the Company’s IPO.

Net_Loss_Per_Share_of_Common_S

Net Loss Per Share of Common Stock	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share of Common Stock	'
	NOTE 5 — NET LOSS PER SHARE OF COMMON STOCK
	Diluted loss per share is the same as basic loss per share for all periods presented as the effects of potentially dilutive issuances were anti-dilutive given the Company’s net loss. Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. The following table sets forth the computation of basic and diluted loss per share for common stockholders:
		Three Months Ended						Nine months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Net loss	$	(27,155,197	)	$	(488,193	)	$	(49,459,277	)	$	(1,135,476	)
	Weighted average shares of common stock outstanding		17,752,371			4,091,027			10,798,432			3,858,687
	Net loss per share of common stock – basic and diluted	$	(1.53	)	$	(0.12	)	$	(4.58	)	$	(0.29	)
	The following securities outstanding at September 30, 2014 and 2013 have been excluded from the calculation of weighted average shares outstanding as their effect on the calculation of loss per share is antidilutive:
		September 30,			September 30,
		2014			2013
	Non-vested stock issued (see Note 9 – Stockholders’ Equity)		—			821,429
	Common stock options		2,621,910			—

License_Agreements

License Agreements	9 Months Ended
	Sep. 30, 2014
License Agreement Disclosure [Abstract]	'
License Agreements	'
	NOTE 6 — LICENSE AGREEMENTS
	In January 2014, the Company renegotiated the structure of the license for MIN-101 such that the Company is required to make milestone payments upon the achievement of one development milestone totaling $0.5 million and certain commercial milestones, which could total up to $47.5 million. In addition, in the event that the Company sells the rights to the license, the licensor will be entitled to a percentage of milestone payments in the low teens and a percentage of royalties received by the Company in the low double digits. Under the terms of the amended agreement, the Company is required to meet a certain diligence obligation to commence a clinical pharmacology study of the licensed compound by the end of April 2015. The Company may extend this deadline for a further year by making an extension payment of $0.5 million. The number of extension payments that may be made is unlimited. In addition, if the Company fails to achieve this development milestone by end of April 2015 or make an extension payment, the licensor may elect to terminate the agreement.
	In January 2014, the Company renegotiated the structure of the license for MIN-117 such that the Company is required to make certain milestone payments upon the achievement of certain commercial milestones up to $47.5 million. In addition, in the event that the Company sells the rights to the license, the licensor will be entitled to a percentage of milestone payments in the low teens and a percentage of royalties received by the Company in the low double digits. Under the terms of the amended agreement, the Company is required to meet a certain diligence obligation to initiate either a Phase II(a) or Phase II(b) study with the licensed compound in patients suffering major mood disorders where initiation is defined as first patient enrolled in the study by the end of April 2015. If the Company fails to achieve this milestone, the Company may elect to extend the timeline to achieve the milestone by one year increments by making an extension payment of $0.5 million. The number of extension payments which may be made is unlimited. In addition, if the Company fails to achieve this development milestone by end April 2015 or make an extension payment, the licensor may elect to terminate the agreement.
	The Company did not make any license payments under the agreements for the three and nine months ended September 30, 2014 and 2013.

DEBT

DEBT	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
DEBT	'
	NOTE 7 — DEBT
	Loans Payable
	In conjunction with the Mind-NRG acquisition on February 11, 2014 (discussed further in Note 3 — Business Combinations), working capital loans were executed between Mind-NRG and several stockholders or affiliates of stockholders for a maximum drawdown of $0.6 million. The loans bear interest at 8% and are repayable at the time the Company completes an IPO or December 1, 2015. The loans may be repaid at any time and contains standard terms of default, under which the interest rate would increase to 11%.
	In April 2014, Mind-NRG repaid the working capital loans plus accrued interest, and certain stockholders and their affiliates subsequently executed new working capital loan agreements, with substantially identical terms, directly with the Company (the April Bridge Loan). The Company drew down the maximum $0.6 million available under the agreement in May 2014.
	In May 2014, the Company entered into a new loan agreement (the May Bridge Loan) with certain stockholders and their affiliates. The Third Loan Agreement provides loan facilities to the Company up to a maximum of $1.0 million. The Third Loan Agreement bears interest at 8% per annum and is repayable at the time the Company completes an IPO or on December 1, 2015. The Third Loan Agreement contains standard terms of default, under which the interest rate would increase to 11% per annum. The Third Loan Agreement provides that any amount outstanding may be repaid at any time without penalty.
	The Company drew down $1.4 million under the April and May Bridge Loan Agreements. In conjunction with the closing of the Company’s IPO on July 7, 2014, the Company repaid the outstanding principal balance under the April and May Bridge Loan agreements plus accrued interest of $11 thousand. Interest expense related to these loans for the three and nine months ended September 30, 2014 was $5 thousand and $16 thousand, respectively, and was included within interest expense (income), net.
	Convertible Promissory Notes
	On November 6, 2013, the Company issued $1.3 million 8% convertible promissory notes due June 30, 2014 to certain stockholders that are payable on demand at maturity. The notes contain certain terms of default, under which conditions the interest rate increases to 11% per annum.
	In conjunction with the merger of Sonkei on November 12, 2013, the Company assumed convertible promissory notes held by certain stockholders with a principal amount of €518,519 ($0.7 million as of July 7, 2014). These notes have a stated interest rate of 8% per annum and a maturity date of June 30, 2014. The notes contains certain terms of default, under which conditions the interest rate increases to 11% per annum. In conjunction with the IPO, the Company’s 8% convertible promissory notes were converted on July 7, 2014 at the IPO price of $6.00 per share into 352,000 shares of the Company’s common stock.
	The notes issued by the Company on November 6, 2013 and the notes issued by Sonkei on November 6, 2013 and subsequently acquired by the Company on November 12, 2013 (collectively, the “Notes”) contained identical terms and were convertible into common shares of the Company under the conditions described below.
	i)	Discount Purchase Option. If the Company sells shares of its capital stock in the qualified financing, as defined, and the convertible promissory notes have not been paid in full, then the outstanding principal balance of these convertible promissory notes and accrued interest thereon shall convert into the common stock sold at the first closing of the qualified financing at a conversion price equal to the price per share paid by the Investors for each share of common stock multiplied by 80%.
	ii)	Initial Public Offering. If the Company conducts an IPO of its common shares before June 30, 2014, then the convertible promissory notes plus accrued interest will convert at the price per share issued in the IPO.
	iii)	$3.50/€3.50 Conversion Option. Subsequent to April 30, 2014, investors may elect to convert the Notes, and accrued interest into common stock of the Company at a conversion price of $3.50 per common share.
	Discount Purchase Option
	The Notes contained an embedded derivative related to the discount purchase feature. The initial fair value of the derivative liability at the date of initial recognition was determined to be $9,976 using a probability-weighted valuation model applying the following assumptions: (i) discount rate of 8.0%, (ii) remaining term of approximately 7 months and (iii) the probabilities of conversion under various circumstances as at the date of measurement. The proceeds allocated to this conversion option of $9,976 were deducted from the initial fair value of the debt obligation. As of December 31, 2013, the fair value of the derivative liability was determined to be $10,093 using a probability-weighted valuation model applying the following assumptions: (i) discount rate of 8.0%, (ii) remaining term of approximately 6 months and (iii) the probabilities of conversion under various circumstances as at the date of measurement.
	Upon conversion of the Notes on July 7, 2014, the fair value of the derivative liability was determined to be $0 and the $10,093 decrease in the fair value of the derivative liability was included as a component of interest for the nine months ended September 30, 2014. No amounts were charged to interest expense during the three months ending September 30, 2014.
	$3.50/€3.50 Conversion Option
	The Notes contained a beneficial conversion feature. The intrinsic value of the beneficial conversion feature was calculated by measuring the difference between the effective conversion price and the fair value of the common stock at initial recognition. The Company recorded a debt discount for the intrinsic value of the beneficial conversion feature that was limited to the proceeds of the Notes received of approximately $2.0 million, with an offsetting increase to additional paid-in capital. The discount was amortized to interest expense using the effective interest method through the date of the Notes’ conversion of July 7, 2014.
	For the three and nine months ended September 30, 2014, the Company recognized interest expense of approximately $3 thousand and $2.0 million related to the Notes, respectively, within interest expense (income), net.

CoDevelopment_and_License_Agre

Co-Development and License Agreement	9 Months Ended
	Sep. 30, 2014
Co Development And License Agreement Disclosure [Abstract]	'
Co-Development and License Agreement	'
	NOTE 8 — CO-DEVELOPMENT AND LICENSE AGREEMENT
	On February 12, 2014, the Company signed a co-development and license agreement with Janssen Pharmaceutica N.V. (“Janssen”) and Janssen Research & Development, LLC (“JJDC”), subject to the completion of an IPO and the payment of a $22.0 million license fee. Under the agreement, the licensor granted the Company an exclusive license, with the right to sublicense, in the European Union, Switzerland, Liechtenstein, Iceland and Norway, referred to as the Minerva Territory, under (i) certain patent and patent applications to sell products containing any orexin 2 compound, controlled by the licensor and claimed in a licensor patent right as an active ingredient and (ii) MIN-202 for any use in humans. In addition, upon regulatory approval in the Minerva Territory (and earlier if certain default events occur), the Company will have rights to manufacture MIN-202. The Company has granted to the licensor an exclusive license, with the right to sublicense, under all patent rights and know-how controlled by the Company related to MIN-202 to sell MIN-202 outside the Minerva Territory.
	In consideration of the licenses granted on July 7, 2014, the Company made a license fee payment of $22.0 million on July 7, 2014, which was included as a component of research and development expense in the third quarter of 2014. The Company will pay a quarterly royalty percentage in the high single digits on aggregate net sales for MIN-202 products sold by the Company, its affiliates and sublicensees in the European Union. The licensor will pay a quarterly royalty percentage to the Company in the high single digits on aggregate net sales for MIN-202 products sold by the licensor outside the European Union.
	In accordance with the development agreement, the Company will pay 40% of MIN-202 development costs related to the joint development of any MIN-202 products. However, the Company’s share of aggregate development costs shall not exceed (i) $5.0 million for the period beginning from the effective date of the license and ending following the completion of certain Phase Ib clinical trials and animal toxicology studies, and (ii) $24.0 million for the period beginning from the effective date of the license and ending following the completion of certain Phase II clinical trials.
	The licensor has a right to opt out at the end of certain development milestones, with the first milestone being the completion of a single day Phase I clinical trial in patients with Major Depressive Disorder (“MDD”). Upon opt out, the licensor will not have to fund further development of MIN-202 and the Minerva Territory will be expanded to also include all of North America. The Company would then owe the licensor a reduced royalty in the mid-single digits for all sales in the Minerva Territory. The Company has the right to terminate the license following certain development milestones the first being completion of a certain Phase Ib clinical trial in patients with insomnia and certain toxicology studies in animals. If the Company terminates the license within 45 days of this milestone, the Company must pay a termination fee equal to $3.0 million. If the Company terminates the license at any time following the last development milestone involving a certain Phase IIb clinical trial, the Company will be entitled to a royalty in the mid-single digits from sales of MIN-202 by the licensor. The licensor may also terminate the agreement for the Company’s material breach or certain insolvency events, including if the Company is unable to fund its portion of the development costs.
	The Company included the $22.0 million license fee payment as a component of research and development expense since the licensed rights were not deemed to have an alternative future use. The Company accounts for the co-development and license agreement as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Payments between the Company and the licensor with respect to each party’s share of MIN-202 development costs that have been incurred pursuant to the joint development plan are recorded within research and development expense or general and administrative expense, as applicable, in the accompanying condensed consolidated financial statements due to the joint risk-sharing nature of the activities. The Company has included $1.4 million in accrued expenses as of September 30, 2014 related to this agreement.
	The Company entered into a common stock purchase agreement with an affiliate of the above mentioned licensor, dated as of February 12, 2014, pursuant to which, among other things, the affiliate agreed to purchase from the Company up to $26.0 million of common stock in a private placement concurrent with the closing of the IPO at a price equal to the IPO price. This investment was consummated simultaneously with the closing of an IPO in July 2014 with the purchase by the affiliate of 3,284,353 shares of common stock resulting in net proceeds to the Company of $19.7 million.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Stockholders Equity Note [Abstract]	'
Stockholders' Equity	'
	NOTE 9 — STOCKHOLDERS’ EQUITY
	Reverse Stock Split
	The board of directors and holders of the requisite number of outstanding shares of our common stock approved an amendment to our restated certificate of incorporation to effect a 3.5-to-1 reverse stock split of our outstanding common stock (the “reverse stock split”) that became effective on June 9, 2014 upon the filing of our Certificate of Amendment of the Restated Certificate of Incorporation with the Delaware Secretary of State. The reverse stock split did not result in an adjustment to par value. All issued and outstanding common stock, warrants for common stock, options to purchase common stock, share transactions, and related per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. On June 9, 2014, the Company amended its Amended and Restated Certificate of Incorporation to increase the total number of authorized shares to 225,000,000 shares, consisting of 125,000,000 shares of common stock, par value $0.0001 per share and 100,000,000 shares of preferred stock, par value $0.0001 per share.
	Initial Public Offering and Concurrent Private Placements
	On July 7, 2014, the Company closed the sale of 5,454,545 shares of its common stock at a price to the public of $6.00 per share, or an aggregate of approximately $32.7 million.  On July 29, 2014, the Company closed the sale of an over-allotment of 160,993 shares of its common stock at a price of $6.00 per share. Net proceeds to the Company from the offering and the over allotment were approximately $28.2 million, after deducting the underwriting discount and expenses of approximately $3.1 million. In addition, the Company closed the sale in a private placement of 666,666 shares of its common stock at a price of $6.00 per share, or an aggregate of approximately $4.0 million.  Net proceeds to the Company were approximately $3.7 million, after deducting the underwriting discount. JJDC purchased 3,284,353 shares of the Company’s common stock in a private placement resulting in net proceeds to the Company of approximately $19.7 million.
	Common Stock Issued for Nonrecourse Notes
	On April 26, 2012, the Company issued 821,429 shares of its common stock in exchange for a nonrecourse note of $3,058,026 (or approximately $3.71 per share, the “Original Price”). The note payable was due in a single installment on February 28, 2014, and was amended to extend the maturity date to September 30, 2014. The note bears interest at the rate of 0.19% per annum and is secured solely by the underlying stock. The stock purchase agreement contains i) a right of first refusal held by the Company, whereby if a third party buyer offers to buy the holder’s stock at a certain price, then the Company has the right to purchase the stock at that same price; and ii) a standard drag-along in case of a sale of the Company. In lieu of payment, the holder is entitled to offset amounts owed under the nonrecourse note in connection with the Company repurchasing common stock from the holder. The Company has the option (a call option) to repurchase the shares if the holder ceases to provide services to the Company or after September 30, 2014, at the Original Price. The holder has the option (a put option) to require the Company to repurchase the shares at any time at the Original Price.
	In accordance with ASC 718-10-25, the purchase of stock in exchange for a nonrecourse note effectively is the same as granting a stock option. If the value of the underlying shares falls below the note amount, the stockholder will relinquish the stock in lieu of repaying the note and would be in the same position as if he or she never purchased the stock. Further, as the shares sold subject to the nonrecourse note are considered an option for accounting purposes, the Company did not record a nonrecourse note or shares outstanding on the balance sheet. The Company also did not recognize interest income on the note as that interest is included in the exercise price of the option. The ultimate holder of the option can only benefit from the instrument if he continues to provide services to the Company through the time of a change in control, as defined. As a change in control was not deemed probable, stock-based compensation expense was not recorded for the year ended December 31, 2013.
	In December 2013, the Company issued 27,925 shares of common stock to the holder, subject to a $97,737 nonrecourse note payable by the holder. The accounting for the additional share issuance is consistent with the 821,429 shares discussed above.
	Sonkei had a similar arrangement with the consultant, whereby Sonkei issued 1,112,500 shares of its common stock in exchange for a nonrecourse note of €1,119,017 (approximately $1.5 million at December 31, 2013). The note payable is due in a single installment on April 30, 2015. The note bears interest at the rate of 0.19% per annum and is secured solely by the underlying stock. As the shares sold subject to the nonrecourse note are considered an option for accounting purposes, the Company did not record a note or shares outstanding on the balance sheet. The Company also did not recognize interest income on the note as that interest is included in the exercise price of the option.
	The ultimate holder of the option can only benefit from the instrument if he continues to provide services to the Company through the time of a change in control, as defined in the applicable agreement. Until a change in control is deemed probable, stock-based compensation expense will not be recorded. The Company assumed this agreement upon the merger with Sonkei, and the Sonkei shares were converted into the Company’s common shares in accordance with the terms of the merger agreement (see Note 3 — Business Combinations).
	On March 31, 2014, the issuer of the $4.7 million nonrecourse notes, which includes accrued interest, remitted to the Company 348,926 shares of common stock with a fair value of $13.51 per share in full settlement of the outstanding note due in a cashless transaction. Additionally, the Company further modified the awards by cancelling the put option and adding a term whereby upon an IPO the award will vest. The remittance of the shares in exchange for settling the outstanding note, the cancellation of the put option, and the addition of the IPO performance condition, represents a modification of the original terms of the stock options. The effect of these changes is that the Company has modified the awards and has converted approximately 1.3 million stock options with an exercise price of $4.7 million to 926,604 shares of non-vested stock (with no exercise price). The non-vested stock remained subject to the above mentioned vesting conditions of a change in control and IPO, which are not deemed probable until they occur. As described in the preceding sentence, the effect of the modification was to replace stock options that were improbable of vesting with non-vested stock that is improbable of vesting and accordingly, the Company did not recognize stock-based compensation expense for the non-vested stock at the time that the vesting conditions are deemed probable of occurrence.  The following is a summary of common shares issued in exchange for nonrecourse notes for the years December 31, 2012 and 2013 and the nine months ended September 30, 2014:
		Common Shares
	Outstanding January 1, 2012		—
	Issued		821,429
	Outstanding December 31, 2012		821,429
	Assumed in Sonkei merger		426,176
	Issued		27,925
	Outstanding December 31, 2013		1,275,530
	Repurchased		(348,926	)
	Shares vested June 30, 2014		926,604
	The 926,604 shares of non-vested common stock held by the consultant became probable of vesting upon the effectiveness of the Company’s IPO registration statement on June 30, 2014, resulting in a charge for stock-based compensation of approximately $10.5 million, representing the 926,604 shares multiplied by the fair value per share on May 1, 2014, the date the consultant became an employee, less previous compensation expense recorded.

Stock_Option_Plan

Stock Option Plan	9 Months Ended
	Sep. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock Option Plan	'
	NOTE 10 — STOCK OPTION PLAN
	The Company adopted the 2013 Equity Incentive Plan (the Plan) in December 2013, which provides for the issuance of options, stock appreciation rights, stock awards and stock units. On April 30, 2014, the Company increased the shares reserved for issuance under the 2013 Equity Incentive Plan to 3,543,754.  The exercise price per share shall not be less than the fair value of the Company’s underlying common stock on the grant date and no option may have a term in excess of ten years. Stock option activity under the Plan is as follows:
				Weighted-Average
		Stock Options		Exercise Price
	Outstanding January 1, 2013		—		—
	Granted		646,759	$	9.49
	Outstanding December 31, 2013		646,759	$	9.49
	Granted		1,975,151	$	6.05
	Outstanding September 30, 2014		2,621,910	$	6.9
	Exercisable September 30, 2014		633,996	$	6.33
	The fair value of each stock option to purchase common stock of the Company granted on December 20, 2013 was estimated by management using the Black-Scholes option pricing model applying the following assumptions: (i) expected term of 5.8 to 10 years, (ii) risk free interest rate of 1.9 to 2.9%, (iii) volatility of 102 to 107%, (iv) no dividend yield and (v) a grant date fair value of common stock of $9.49 per share. The Company recognized stock-based compensation expense for the three and nine months ended September 30, 2014 related to these options of $0.3 million and $0.9 million, respectively, which is included in general and administrative expense.
	The table above includes stock options granted on December 20, 2013 to purchase an aggregate of 20,089 shares of the Company’s common stock which became fully vested and exercisable on June 30, 2014, the effective date of the Company’s IPO registration statement.  The Company recognized stock-based compensation expense for the nine months ended September 30, 2014 related to these options of $0.1 million, which is included in general and administrative expense.
	The Company entered into two employment agreements effective May 1, 2014. In accordance with the employment agreements, on June 30, 2014, the Company granted 539,116 fully vested stock options to purchase shares of the Company’s common shares at an exercise price of $6.00 per share and recognized stock based compensation expense of approximately $2.8 million related to these grants on the grant date. The fair value of each such option was estimated by management using the Black Scholes option pricing model applying the following assumptions: (i) expected term of 6.25 years, (ii) risk free interest rate of 1.9%, (iii) volatility of 113%, (iv) no dividend yield and (v) a grant date fair value of common stock of $6.00 per share.
	Under the terms of three employment agreements, the Company issued 955,932 stock options upon the effective date of the Company's IPO registration statement, which vest over a four-year period beginning from November 12, 2013, the date of the Sonkei Merger.  The Company recognized stock-based compensation expense related to these options of approximately $0.3 million and $1.1 million for the three and nine months ended September 30, 2014, respectively.  The fair value of each such option was estimated by management using the Black Scholes option pricing model applying the following assumptions: (i) expected term of 6.25 years, (ii) risk free interest rate of 1.9%, (iii) volatility of 113%, (iv) no dividend yield and (v) a grant date fair value of common stock of $6.00 per share.
	An additional 480,103 options were granted to employees and directors at and following the IPO of which 352,590 options vest over a four year period and 127,513 options vest over a three year period beginning with the date each recipient began providing service. The Company recognized stock-based compensation expense related to these options of approximately $0.3 million and $0.3 million for the three and nine months ended September 30, 2014, respectively.  The fair value of each of these options to purchase common stock of the Company granted was estimated by management using the Black Scholes option pricing model applying the following assumptions: (i) expected term of 6-6.25 years, (ii) risk free interest rate of 1.9%, (iii) volatility of 113%, (iv) no dividend yield.
	The weighted average grant-date fair value of stock options outstanding on September 30, 2014 was $5.81 per share. Total unrecognized compensation costs related to non-vested awards at September 30, 2014 was approximately $9.6 million and is expected to be recognized within future operating results over a period of 3.1 years. At September 30, 2014, the weighted average contractual term of the options outstanding is approximately 9.6 years. The intrinsic value of outstanding stock options at September 30, 2014 was $0.1 million.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	NOTE 11 — INCOME TAXES
	There was no provision for income taxes for the three and nine month periods ended September 30, 2014 and 2013 due to losses.
	As of December 31, 2013, the Company has approximately $16.0 million of Federal net operating losses that will begin to expire in 2027. As of December 31, 2013, the Company had approximately $11.0 million of New Jersey operating losses that will begin to expire in 2014. As of December 31, 2013, the Company had approximately $0.2 million of federal research and development credits that will begin to expire in 2027. The Internal Revenue Code of 1986, as amended (“IRC”) limits the amounts of net operating loss carryforwards that a company may use in any one year in the event of certain cumulative changes in ownership over a three-year period as described in Section 382 of the IRC. The Company has not performed a detailed analysis to determine whether an ownership change has occurred as of December 31, 2013.
	Deferred tax liabilities related to indefinite-lived assets typically are not used as a source of income to support realization of deferred tax assets in jurisdictions where tax attributes expire (e.g., jurisdictions where net operating loss carryforwards expire) unless the deferred tax liability is expected to reverse prior to the expiration date of the tax attribute. Therefore, the net operating losses of Sonkei cannot be used to offset the deferred tax liability resulting from the IPR&D due to the fact that the IPR&D currently has an indefinite life while the NOLs have a maximum life of 20 years.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments	'
	NOTE 12 — COMMITMENTS
	In September 2014, the Company entered into a lease agreement for 4,043 square feet of office space in Waltham, MA. The term of the lease is approximately 2 years, and the Company is required to make monthly rental payments commencing December 2014. Estimated annual rent payable under this operating lease is approximately $0.1 million per year in each of the two years.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	NOTE 13 — RELATED PARTY TRANSACTIONS
	An investor provided accounting and other services to the Company and Sonkei for $60 thousand in the aggregate per year during 2013 and early 2014. For the nine months ended September 30, 2014 and 2013, the expense recognized in operating results in connection with these services was $35 thousand and $45 thousand, respectively.  For the three months ended September 30, 2014 and 2013, the expense recognized in operating results in connection with these services was $0 and $15 thousand, respectively.
	The Company retained the services of certain consultants who were also stockholders of the Company.  For the nine months ended September 30, 2014 and 2013, the expense recognized by the Company in connection with these services was $0.3 million and $0.3 million, respectively. For the three months ended September 30, 2014 and 2013, the expense recognized by the Company in connection with these services was $0 and $0.1 million, respectively.
	Also refer to Note 8 – Co-Development and License Agreement and Note 9 – Stockholder’s Equity for additional related party transactions.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of presentation
	The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all adjustments (consisting of items of a normal and recurring nature) necessary to present fairly the financial position as of September 30, 2014 and the results of operations for the three and nine months ended September 30, 2014 and 2013 and cash flows for the nine months ended September 30, 2014 and 2013. The results of operations for the three and nine months ended September 30, 2014, are not necessarily indicative of the results to be expected for the full year. When preparing financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.
	Actual results could differ from those estimates. The balance sheet as of December 31, 2013 was derived from the audited financial statements. The accompanying unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited financial statements for the years ended December 31, 2013 and 2012.
	From its inception the Company has devoted substantially all of its efforts to business planning, engaging regulatory, manufacturing and other technical consultants, planning and executing clinical trials and raising capital.
Consolidation	'
	Consolidation
	The accompanying consolidated financial statements include the results of the Company and its wholly-owned subsidiary, Mind-NRG. Intercompany transactions have been eliminated.
Significant Risks and Uncertainties	'
	Significant risks and uncertainties
	The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of and demand for Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital.
	The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.
Use of Estimates	'
	Use of estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
	Prior to the completion of the Company’s IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The board of directors determined the estimated fair value of the Company’s common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, discounted cash flows and the likelihood of achieving a liquidity event, such as an IPO of common stock or a sale of the Company. The Company utilized various valuation methodologies in accordance with the framework of the 2013 American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. The methodologies included a probability-weighted expected return methodology that determined an estimated value under an IPO scenario and a sale scenario based upon an assessment of the probability of occurrence of each scenario. Each valuation methodology includes estimates and assumptions that require the Company’s judgment. These estimates include assumptions regarding future performance, including the successful completion of preclinical studies and clinical trials and the time to complete an IPO or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.
Research and Development Costs	'
	Research and development costs
	Costs incurred in connection with research and development activities are expensed as incurred. These costs include licensing fees to use certain technology in the Company’s research and development projects as well as fees paid to consultants and various entities that perform certain research and testing on behalf of the Company. We determine our expenses related to clinical studies based on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual accordingly. The expenses for some trials may be recognized on a straight-line basis if the expected costs are expected to be incurred ratably during the period. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the condensed consolidated financial statements as prepaid or accrued expenses.
	In July 2014, the Company paid a $22.0 million license fee, which has been included as a component of research and development expense since the licensed rights were not deemed to have an alternative future use. The Company accounts for the co-development and license agreement pursuant to which the license fee was paid as a joint risk-sharing collaboration in accordance with ASC 808, Collaboration Arrangements. Costs between the Company and the licensor with respect to each party’s share of development costs that have been incurred pursuant to the joint development plan are recorded within research and development expense or general and administrative expense, as applicable, in the accompanying condensed consolidated financial statements due to the joint risk-sharing nature of the activities. The Company has included $1.4 million in accrued expenses as of September 30, 2014 related to this agreement.
	In-process research and development (“IPR&D”) assets represent capitalized incomplete research projects that the Company acquired through business combinations. Such assets are initially measured at their acquisition date fair values. The fair value of the research projects is recorded as intangible assets on the balance sheet, rather than expensed, regardless of whether these assets have an alternative future use.
	The amounts capitalized are being accounted for as indefinite-lived intangible assets, subject to impairment testing, until completion or abandonment of research and development efforts associated with the project. An IPR&D asset is considered abandoned when it ceases to be used (that is, research and development efforts associated with the asset have ceased, and there are no plans to sell or license the asset or derive defensive value from the asset). At that point, the asset is considered to be disposed of and is written off. Upon successful completion of each project, the Company will make a determination about the then remaining useful life of the intangible asset and begin amortization. The Company tests its indefinite-lived intangibles, IPR&D assets, for impairment annually on November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. When testing indefinite-lived intangibles for impairment, the Company may assess qualitative factors for its indefinite-lived intangibles to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the asset is impaired. Alternatively, the Company may bypass this qualitative assessment for some or all of its indefinite-lived intangibles and perform the quantitative impairment test that compares the fair value of the indefinite- lived intangible asset with the asset’s carrying amount.
Stock-Based Compensation	'
	Stock-based compensation
	The Company recognizes compensation cost relating to share-based payment transactions in operating results using a fair-value measurement method, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Series Codification (“ASC”) -718 Compensation-Stock Compensation. ASC-718 requires all share-based payments to employees, including grants of employee stock options, to be recognized in operating results as compensation expense over the requisite service period of the awards based on fair value of the granted instruments. The Company determines the fair value of share-based awards using the Black-Scholes option pricing model, which uses both historical and current market data to estimate fair value. This model incorporates various assumptions such as the risk-free interest rate, the expected volatility of the Company’s stock price, the stock’s expected dividend yield and the expected life of the options. The Company reduces the amount of compensation expense it recognizes for the expected amount of pre-vesting forfeitures.
	Grants to non-employees are accounted for in accordance with ASC-505-50 Equity — Based Payments to Non-Employees. The fair value of the instruments awarded are remeasured until the earlier of the date at which a commitment for performance by the counterparty to earn the equity instrument is reached or the date at which the counterparty’s performance is complete. The Company determines the fair value of share-based awards granted to non-employees using the Black-Scholes option pricing model.
Loss Per Share	'
	Loss per share
	Basic loss per share excludes dilution and is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the entity.
Income Taxes	'
	Income taxes
	The Company utilizes the liability method of accounting for income taxes as required by ASC Topic 740 Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax reporting bases of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Deferred tax assets are evaluated for realization based on a more-likely-than-not criterion in determining if a valuation allowance should be provided. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.
	ASC Topic 740 also covers the accounting for uncertainty in income taxes recognized in the consolidated financial statements. The guidance prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. ASC Topic 740 provides guidance on the recognition of interest and penalties related to income taxes. There were no interest or penalties related to income taxes for the three and nine months ended September 30, 2014 and 2013. The Company has elected to treat interest and penalties, to the extent they arise, as a component of income taxes. Income tax years beginning in 2011 for federal and state purposes are generally subject to examination by taxing authorities, although net operating losses from all prior years are subject to examinations and adjustments for at least three years following the year in which the tax attributes are utilized.
Deferred Public Offering Costs	'
	Deferred public offering costs
	Deferred public offering costs include certain legal, accounting and other costs directly attributable to the Company’s public offering of common stock. Upon completion of the Company’s IPO on July 7, 2014, these amounts were offset against the proceeds of the offering.
Business Combinations	'
	Business combinations
	For business combinations the Company utilizes the acquisition method of accounting in accordance with ASC Topic 805, Business Combinations. These standards require that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based their respective fair values at the date of acquisition. The allocation of the purchase price is dependent upon certain valuations and other studies. Acquisition costs are expensed as incurred. The Company recognizes separately from goodwill the fair value of assets acquired and the liabilities assumed. Goodwill as of the acquisition date is measured as the excess of consideration transferred and the acquisition date fair values of the assets acquired and liabilities assumed. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the Company’s estimates are subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, the Company may retroactively record adjustments to the fair value of the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the fair value of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to the Company’s consolidated statements of operations.
Goodwill	'
	Goodwill
	The Company tests its goodwill for impairment annually, or whenever events or changes in circumstances indicate an impairment may have occurred, by comparing its reporting unit’s carrying value to its implied fair value. Impairment may result from, among other things, deterioration in the performance of the acquired business, adverse market conditions, adverse changes in applicable laws or regulations and a variety of other circumstances. If the Company determines that an impairment has occurred, it is required to record a write-down of the carrying value and charge the impairment as an operating expense in the period the determination is made. In evaluating the recoverability of the carrying value of goodwill the Company must make assumptions regarding estimated future cash flows and other factors to determine the fair value of the acquired assets. Changes in strategy or market conditions could significantly impact those judgments in the future and require an adjustment to the recorded balances. The Company tests its goodwill for impairment annually at November 30 and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. There was no impairment of goodwill for the year ended December 31, 2013 and the Company believes there was no impairment for the three and nine months ended September 30, 2014.
Convertible Promissory Notes	'
	Convertible promissory notes
	The Company had issued 8% convertible promissory notes consisting of (i) $1.3 million face value convertible promissory notes and(ii) €518,519 face value convertible promissory notes. The Euro denominated notes were acquired in conjunction with the merger with Sonkei (discussed further in Note 3 — Business Combinations), and recorded at their fair value of approximately $0.7 million on the date of the merger.
	In conjunction with the IPO, the Company’s 8% convertible promissory notes in the face amount of $1.3 million and €518,519 including $0.1 million in accrued interest, were converted on July 7, 2014 at the IPO price of $6.00 per share into 352,000 shares of the Company’s common stock. There were no debt instruments outstanding on September 30, 2014.
	Discount Purchase Option
	The Company’s 8% convertible promissory notes contain an embedded derivative related to the conversion option containing a discount purchase feature in a qualified financing, as defined in such convertible promissory notes. The derivative was carried at fair value and was classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs. As of December 31, 2013, the fair value of the derivative liability was determined to be $10,093 using a probability-weighted valuation model applying the following assumptions: (i) discount rate of 8.0%, (ii) remaining term of approximately 6 months and (iii) the probabilities of conversion under various circumstances as at the date of measurement. The fair value of the derivative liability was remeasured at the July 7, 2014 conversion date and the fair value of the liability was determined to be $0. The $10,093 decrease in the fair value of the derivative liability was included as a component of interest for the nine months ended September 30, 2014. No amounts were charged to interest during the three months ended September 30, 2014.
	$3.50/€3.50 Conversion Option
	The Company’s 8% convertible promissory notes contained an embedded derivative related to the beneficial conversion feature of the notes. The initial fair value of the derivative liability at the date of issuance in November 2013 was determined by measuring the difference between the conversion price and the fair value of common stock at the commitment date. The Company recorded a debt discount for the fair value of the derivative, which was limited to the proceeds received of approximately $2.0 million, with an offsetting increase to additional paid-in capital. The beneficial conversion charge was included in the balance sheet at December 31, 2013 as a discount to the related convertible promissory notes. The discount was accreted as non-cash interest expense over the term of the debt using the effective interest method. The debt was converted into common stock in conjunction with the Company’s IPO on July 7, 2014 and the Company recognized approximately $0 and $2.0 million in non-cash interest expense within interest expense (income), net during the three and nine month periods ended September 30, 2014, respectively.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by FASB and are adopted by the Company as of the specified effective date. The Company believes that the impact of other recently issued but not yet adopted accounting pronouncements will not have a material impact on the financial position, results of operations, and cash flows, or do not apply to the Company’s operations.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915) which eliminates the definition of a development stage entity and removes the financial reporting distinction between development stage entities and other reporting entities under GAAP.  The Company early adopted this standard and thus has eliminated its historical inception to date information in the financial statements.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40) which provides guidance on disclosure requirements when there is substantial doubt about an entity’s ability to continue as a going concern. The amendments in this update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter, with early adoption permitted. The Company will evaluate this amendment but does not believe that it will have a material impact on its financial position, results of operations or cash flows.

Business_Combinations_Tables

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2014
Pro Forma Results	'
	The unaudited pro forma financial information below is for informational purposes only and is not indicative of the results of operations or financial condition that would have been achieved if the merger would have taken place at the beginning of each of the periods presented and should not be taken as indicative of the Company’s future results of operations or financial condition.
		Three Months Ended						Nine months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Operating loss	$	(27,155,197	)	$	(1,110,023	)	$	(49,912,152	)	$	(2,682,000	)
	Loss per share	$	(1.53	)	$	(0.15	)	$	(4.53	)	$	(0.37	)
Mind-NRG	'
Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed	'
	The aggregate consideration of $16.5 million has been allocated to assets acquired and liabilities assumed based on estimated fair values at the February 11, 2014 as follows:
	Cash	$	1,167,869
	Other assets		71,130
	Goodwill		7,076,412
	In-process research and development		15,200,000
	Deferred tax liability		(5,970,560	)
	Accrued expenses		(321,417	)
	ProteoSys milestone payable		(681,600	)
		$	16,541,834
Sonkei	'
Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed	'
	The aggregate consideration of $18.9 million has been allocated to assets acquired and liabilities assumed based on estimated fair values at the date of merger November 12, 2013 as follows:
	Cash	$	631,478
	Goodwill		7,792,987
	In-process research and development		19,000,000
	Accrued expenses		(334,423	)
	Derivative liability		(3,476	)
	Deferred taxes		(7,463,200	)
	Convertible promissory notes (see Note 7)		(680,000	)
		$	18,943,366

Accrued_Expenses_and_Other_Lia1

Accrued Expenses and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Payables And Accruals [Abstract]	'
Schedule of Accrued Expenses and Other Liabilities	'
	Accrued expenses and other liabilities consist of the following:
		September 30, 2014		December 31, 2013
	Accrued payroll	$	229,785	$	126,910
	Accrued excise and franchise taxes		203,991		—
	Research and development costs		168,640		58,117
	Primomed research funding (1)		132,721		—
	Professional fees (2)		70,445		595,215
	Consulting and other costs		27,024		5,031
	Vacation pay		17,818		5,690
	Interest payable		—		24,276
		$	850,424	$	815,239
	-1	Under the terms of a research agreement with Primomed, the Company received grant funds that will be used to offset certain costs under the MIN-301 development program.
	-2	Accounts payable and accrued professional fees at December 31, 2013 included $0.4 million that was incurred in connection with the preparation for the Company’s IPO.

Net_Loss_Per_Share_of_Common_S1

Net Loss Per Share of Common Stock (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Computation of Basic and Diluted Loss Per Share	'
	The following table sets forth the computation of basic and diluted loss per share for common stockholders:
		Three Months Ended						Nine months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Net loss	$	(27,155,197	)	$	(488,193	)	$	(49,459,277	)	$	(1,135,476	)
	Weighted average shares of common stock outstanding		17,752,371			4,091,027			10,798,432			3,858,687
	Net loss per share of common stock – basic and diluted	$	(1.53	)	$	(0.12	)	$	(4.58	)	$	(0.29	)
Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive	'
	The following securities outstanding at September 30, 2014 and 2013 have been excluded from the calculation of weighted average shares outstanding as their effect on the calculation of loss per share is antidilutive:
		September 30,			September 30,
		2014			2013
	Non-vested stock issued (see Note 9 – Stockholders’ Equity)		—			821,429
	Common stock options		2,621,910			—

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Stockholders Equity Note [Abstract]	'
Summary of Common Shares Issued in Exchange for Nonrecourse Notes	'
	The following is a summary of common shares issued in exchange for nonrecourse notes for the years December 31, 2012 and 2013 and the nine months ended September 30, 2014:
		Common Shares
	Outstanding January 1, 2012		—
	Issued		821,429
	Outstanding December 31, 2012		821,429
	Assumed in Sonkei merger		426,176
	Issued		27,925
	Outstanding December 31, 2013		1,275,530
	Repurchased		(348,926	)
	Shares vested June 30, 2014		926,604

Stock_Option_Plan_Tables

Stock Option Plan (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Stock Option Activity	'
	Stock option activity under the Plan is as follows:
				Weighted-Average
		Stock Options		Exercise Price
	Outstanding January 1, 2013		—		—
	Granted		646,759	$	9.49
	Outstanding December 31, 2013		646,759	$	9.49
	Granted		1,975,151	$	6.05
	Outstanding September 30, 2014		2,621,910	$	6.9
	Exercisable September 30, 2014		633,996	$	6.33

Recovered_Sheet1

NATURE OF OPERATIONS AND LIQUIDITY - Additional Information (Details) (USD $)	1 Months Ended	9 Months Ended			0 Months Ended		1 Months Ended
	Jul. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Jul. 07, 2014	Jul. 07, 2014	Jul. 31, 2014	Feb. 11, 2014
					IPO	Second Private Placement	Co-development and License Agreement	Mind-NRG
							MIN-202
Nature Of Operations And Liquidity [Line Items]	'	'	'	'	'	'	'	'
Share capital acquired (as a percent)	'	'	'	'	'	'	'	100.00%
Payment of initial upfront license fee	$22,000,000	'	'	'	'	'	$22,000,000	'
Accumulated deficit	'	-67,289,068	'	-17,829,791	'	'	'	'
Net proceeds from IPO	'	31,334,702	'	'	28,200,000	'	'	'
Proceeds from issuance of private placement	'	$23,706,118	$1,850,000	'	'	$23,400,000	'	'

Recovered_Sheet2

SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)

0 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Jul. 07, 2014

Jul. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Nov. 06, 2013

Nov. 06, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Nov. 12, 2013

Nov. 12, 2013

Sep. 30, 2014

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

8% Convertible Promissory Notes

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

Sonkei

Sonkei

Sonkei

Sonkei

USD ($)

USD ($)

EUR (€)

USD ($)

EUR (€)

Significant Accounting Policies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payment of initial upfront license fee

'

$22,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued collaborative expenses

'

'

1,386,493

1,386,493

'

'

'

'

'

'

'

'

'

'

'

Interest or penalties related to income taxes

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

Impairment of goodwill

'

'

0

0

0

'

'

'

'

'

'

'

'

'

'

Interest rate (as a percent)

8.00%

'

'

'

'

8.00%

8.00%

8.00%

8.00%

'

'

'

8.00%

8.00%

'

Face value

'

'

'

'

'

1,300,000

'

1,300,000

1,300,000

'

700,000

518,519

680,000

518,519

'

Accrued interest

'

'

'

'

24,276

'

'

'

'

'

'

'

'

'

100,000

Conversion price (in dollars per share)

$6

'

'

'

'

$3.50

€ 3.50

'

'

'

'

'

'

'

$6

Conversion of debt to common stock (in shares)

352,000

'

'

'

'

'

'

'

'

'

'

'

'

'

352,000

Decrease in fair value of the derivative liability

'

'

'

10,093

'

'

'

'

'

10,093

'

'

'

'

'

Remaining term

'

'

'

'

'

'7 months

'7 months

'

'

'6 months

'

'

'

'

'

Discount rate (as a percent)

'

'

'

'

'

8.00%

8.00%

'

'

8.00%

'

'

'

'

'

Unamortized debt discount

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

Amortization of debt discount recorded as interest expense

'

'

'

$1,952,309

'

'

'

$0

$1,952,309

'

'

'

'

'

'

BUSINESS_COMBINATIONS_MindNRG_

BUSINESS COMBINATIONS - Mind-NRG Acquisition - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended			0 Months Ended	3 Months Ended	9 Months Ended		0 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Nov. 12, 2013	Feb. 12, 2014	Sep. 30, 2014	Sep. 30, 2014	Feb. 11, 2014	Feb. 12, 2014
						Mind-NRG	Mind-NRG	Mind-NRG	Mind-NRG	Mind-NRG
										Shares Held In Escrow
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'
Number of shares of common stock	'	'	'	'	'	1,481,583	'	'	'	148,160
Aggregate consideration	'	'	'	'	'	$16,500,000	'	'	'	'
Estimated fair value (in dollars per share)	'	'	'	'	'	'	'	'	$11.17	'
Share capital acquired (as a percent)	'	'	'	'	'	'	'	'	100.00%	'
Deferred tax liability	'	'	'	'	7,463,200	'	'	'	5,970,560	'
Increase (decrease) in deferred taxes	'	'	'	'	'	'	-100,000	'	'	'
Operating Income Loss	($27,151,351)	($482,472)	($47,424,514)	($1,132,589)	'	'	'	($1,300,000)	'	'

BUSINESS_COMBINATIONS_Aggregat

BUSINESS COMBINATIONS - Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed of Mind-NRG Acquisition (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Nov. 12, 2013	Feb. 11, 2014	Feb. 11, 2014	Feb. 11, 2014
				Mind-NRG	Mind-NRG	Mind-NRG
					In-Process Research and Development	ProteoSys
Assets acquired and liabilities assumed based on estimated fair values	'	'	'	'	'	'
Cash	'	'	'	$1,167,869	'	'
Other assets	'	'	'	71,130	'	'
Goodwill	14,869,399	7,918,387	'	7,076,412	'	'
In-process research and development	'	'	'	'	15,200,000	'
Deferred tax liability	'	'	-7,463,200	-5,970,560	'	'
Accrued expenses	'	'	'	-321,417	'	'
Milestone payable	'	'	'	'	'	-681,600
Total	'	'	'	$16,541,834	'	'

BUSINESS_COMBINATIONS_Sonkei_M

BUSINESS COMBINATIONS - Sonkei Merger - Additional Information (Details)

Nov. 12, 2013

Sep. 30, 2014

Nov. 06, 2013

Sep. 30, 2014

Nov. 12, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Nov. 12, 2013

Nov. 12, 2013

Nov. 12, 2013

Nov. 12, 2013

USD ($)

Convertible Promissory Notes

Convertible Promissory Notes

Common Stock

Sonkei

Sonkei

Sonkei

Sonkei

Sonkei

Sonkei

Sonkei

Sonkei

USD ($)

USD ($)

USD ($)

USD ($)

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Common Stock

Nonemployee Holding Common Stock With Nonrecourse Note

USD ($)

EUR (€)

USD ($)

EUR (€)

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Conversion ratio

'

'

'

'

0.383

'

'

'

'

'

'

'

Number of shares of common stock

'

'

'

'

2,423,368

'

'

'

'

'

'

'

Number of shares held

'

'

'

'

'

'

'

'

'

'

'

1,112,500

Number of shares issued

'

'

'

'

'

'

'

'

'

'

'

426,176

Issuance of shares for business acquisition (in shares)

'

'

'

1,481,583

'

'

'

'

'

'

1,997,192

'

Aggregate consideration

'

'

'

'

$18,900,000

'

'

'

'

'

'

'

Estimated fair value (in dollars per share)

'

'

'

'

$9.49

'

'

'

'

'

'

'

Principal amount

'

1,300,000

1,300,000

'

'

'

700,000

518,519

680,000

518,519

'

'

Deferred tax liability

7,463,200

'

'

'

7,463,200

'

'

'

'

'

'

'

Net operating losses

'

'

'

'

5,300,000

'

'

'

'

'

'

'

Increase (decrease) in deferred taxes

'

'

'

'

'

($100,000)

'

'

'

'

'

'

BUSINESS_COMBINATIONS_Aggregat1

BUSINESS COMBINATIONS - Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed of Sonkei Merger (Details)	Sep. 30, 2014	Dec. 31, 2013	Nov. 12, 2013	Sep. 30, 2014	Nov. 06, 2013	Nov. 12, 2013	Nov. 12, 2013	Sep. 30, 2014	Sep. 30, 2014	Nov. 12, 2013	Nov. 12, 2013
	USD ($)	USD ($)	USD ($)	Convertible Promissory Notes	Convertible Promissory Notes	Sonkei	Sonkei	Sonkei	Sonkei	Sonkei	Sonkei
				USD ($)	USD ($)	USD ($)	In-Process Research and Development	Convertible Promissory Notes	Convertible Promissory Notes	Convertible Promissory Notes	Convertible Promissory Notes
							USD ($)	USD ($)	EUR (€)	USD ($)	EUR (€)
Assets acquired and liabilities assumed based on estimated fair values	'	'	'	'	'	'	'	'	'	'	'
Cash	'	'	'	'	'	$631,478	'	'	'	'	'
Goodwill	14,869,399	7,918,387	'	'	'	7,792,987	'	'	'	'	'
In-process research and development	'	'	'	'	'	'	19,000,000	'	'	'	'
Accrued expenses	'	'	'	'	'	-334,423	'	'	'	'	'
Derivative liability	'	'	'	'	'	-3,476	'	'	'	'	'
Deferred tax liability	'	'	-7,463,200	'	'	-7,463,200	'	'	'	'	'
Convertible promissory notes (see Note 7)	'	'	'	-1,300,000	-1,300,000	'	'	-700,000	-518,519	-680,000	-518,519
Total	'	'	'	'	'	$18,943,366	'	'	'	'	'

BUSINESS_COMBINATIONS_Pro_Form

BUSINESS COMBINATIONS - Pro Forma Results (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Unaudited pro forma financial information	'	'	'	'
Operating loss	($27,155,197)	($1,110,023)	($49,912,152)	($2,682,000)
Loss per share	($1.53)	($0.15)	($4.53)	($0.37)

Recovered_Sheet3

ACCRUED EXPENSES AND OTHER LIABILITIES - Accrued Expenses and Other Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Payables And Accruals [Abstract]	'	'
Accrued payroll	$229,785	$126,910
Accrued excise and franchise taxes	203,991	'
Research and development costs	168,640	58,117
Primomed research funding	132,721	'
Professional fees	70,445	595,215
Consulting and other costs	27,024	5,031
Vacation pay	17,818	5,690
Interest payable	'	24,276
Accrued expenses and other liabilities	$850,424	$815,239

Recovered_Sheet4

ACCRUED EXPENSES AND OTHER LIABILITIES - Accrued Expenses and Other Liabilities (Parenthetical) (Details) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Payables And Accruals [Abstract]	'
Cost incurred in connection with the preparation for the Company's IPO included in accrued professional fees	$0.40

Recovered_Sheet5

NET LOSS PER SHARE OF COMMON STOCK - Computation of Basic and Diluted Loss Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net loss	($27,155,197)	($488,193)	($49,459,277)	($1,135,476)
Weighted average shares of common stock outstanding	17,752,371	4,091,027	10,798,432	3,858,687
Net loss per share of common stock b basic and diluted	($1.53)	($0.12)	($4.58)	($0.29)

Recovered_Sheet6

NET LOSS PER SHARE OF COMMON STOCK - Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2014
	Non-vested stock issued	Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Securities outstanding excluded from the calculation of weighted average shares outstanding	821,429	2,621,910

LICENSE_AGREEMENTS_Additional_

LICENSE AGREEMENTS - Additional Information (Details) (License Agreement, Mitsubishi, USD $)	1 Months Ended
In Millions, unless otherwise specified	Jan. 31, 2014
	item
MIN-101	'
License Agreement	'
Potential milestone payments upon achievement of milestone	$0.50
Number of development milestones required	1
Potential extension payment	0.5
MIN-101 | Maximum	'
License Agreement	'
Potential milestone payments upon achievement of milestone	47.5
MIN-117	'
License Agreement	'
Potential extension payment	0.5
Term of extension of the agreement	'1 year
MIN-117 | Maximum	'
License Agreement	'
Potential milestone payments upon achievement of milestone	$47.50

DEBT_Loans_Payable_Additional_

DEBT - Loans Payable - Additional Information (Details) (USD $)	3 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2014	Jul. 07, 2014	Sep. 30, 2014	Sep. 30, 2014	31-May-14	Feb. 11, 2014	Nov. 06, 2013	31-May-14	Feb. 11, 2014	Nov. 06, 2013
			Bridge Loan	Bridge Loan	Bridge Loan	Bridge Loan	Bridge Loan	Bridge Loan	Bridge Loan	Bridge Loan
								Under Standard Terms of Default	Under Standard Terms of Default	Under Standard Terms of Default
Debt	'	'	'	'	'	'	'	'	'	'
Maximum drawdown amount	'	'	'	'	$1,000,000	$600,000	'	'	'	'
Percentage of interest rate on loan	'	8.00%	'	'	8.00%	8.00%	8.00%	11.00%	11.00%	11.00%
Balance outstanding	1,400,000	'	'	'	600,000	'	'	'	'	'
Accrued Interest repaid	'	'	'	11,000	'	'	'	'	'	'
Interest Expense	$0	'	$5,000	$16,000	'	'	'	'	'	'

DEBT_Convertible_Promissory_No

DEBT - Convertible Promissory Notes - Additional Information (Details)

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

Jul. 07, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Nov. 06, 2013

Nov. 06, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Jul. 07, 2014

Sep. 30, 2014

Sep. 30, 2014

Nov. 12, 2013

Nov. 12, 2013

Sep. 30, 2014

Sep. 30, 2014

31-May-14

Feb. 11, 2014

Nov. 06, 2013

Nov. 12, 2013

31-May-14

Feb. 11, 2014

Nov. 06, 2013

USD ($)

USD ($)

USD ($)

USD ($)

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Convertible Promissory Notes

Bridge Loan

Bridge Loan

Bridge Loan

Bridge Loan

Bridge Loan

Under Standard Terms of Default

Under Standard Terms of Default

Under Standard Terms of Default

Under Standard Terms of Default

USD ($)

EUR (€)

USD ($)

USD ($)

USD ($)

USD ($)

Sonkei

Sonkei

Sonkei

Sonkei

USD ($)

USD ($)

Convertible Promissory Notes

Bridge Loan

Bridge Loan

Bridge Loan

USD ($)

EUR (€)

USD ($)

EUR (€)

Sonkei

Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of interest rate on loan

8.00%

'

'

'

8.00%

8.00%

8.00%

8.00%

'

'

'

'

8.00%

8.00%

'

'

8.00%

8.00%

8.00%

11.00%

11.00%

11.00%

11.00%

Principal amount

'

'

'

'

$1,300,000

'

$1,300,000

$1,300,000

'

'

$700,000

€ 518,519

$680,000

€ 518,519

'

'

'

'

'

'

'

'

'

Conversion price (in dollars per share)

$6

'

'

'

$3.50

€ 3.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of debt to common stock (in shares)

352,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage multiplied to price per share paid by the Investors for each share of common stock to determine conversion price

'

'

'

'

80.00%

80.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative liability

'

'

'

10,093

9,976

'

'

'

10,093

0

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate (as a percent)

'

'

'

'

8.00%

8.00%

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Remaining term

'

'

'

'

'7 months

'7 months

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Decrease in fair value of the derivative liability

'

'

10,093

'

'

'

'

'

10,093

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest Expense

'

0

'

'

'

'

3,000

2,000,000

'

'

'

'

'

'

5,000

16,000

'

'

'

'

'

'

'

Unamortized debt discount

'

'

'

'

$2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Recovered_Sheet7

CO-DEVELOPMENT AND LICENSE AGREEMENT - Additional Information (Details) (USD $)	1 Months Ended		0 Months Ended			0 Months Ended	1 Months Ended	0 Months Ended
	Jul. 31, 2014	Sep. 30, 2014	Jul. 07, 2014	Feb. 12, 2014	Sep. 30, 2014	Feb. 12, 2014	Jul. 31, 2014	Feb. 12, 2014	Feb. 12, 2014
			Common Stock Purchase Agreement	Common Stock Purchase Agreement	MIN-202	MIN-202	MIN-202	MIN-202	MIN-202
				Maximum		Co-development and License Agreement	Co-development and License Agreement	Co-development and License Agreement	Co-development and License Agreement
								Period one	Period two
								Maximum	Maximum
Co-development and license agreement	'	'	'	'	'	'	'	'	'
Payment of initial upfront license fee	$22,000,000	'	'	'	'	'	$22,000,000	'	'
Percentage of development costs related to joint development of products	'	'	'	'	'	40.00%	'	'	'
Share of aggregate development cost following completion of Phase Ib clinical trials and animal toxicology studies	'	'	'	'	'	'	'	5,000,000	24,000,000
Period within which agreement is terminated related to Phase Ib clinical trials milestone	'	'	'	'	'	'45 days	'	'	'
Termination fee related to Phase Ib clinical trial milestone	'	'	'	'	'	3,000,000	'	'	'
Accrued collaborative expenses	'	1,386,493	'	'	1,386,493	'	'	'	'
Common stock agreed to be issued (in shares)	'	'	'	26,000,000	'	'	'	'	'
Common stock issued (in shares)	'	'	3,284,353	'	'	'	'	'	'
Net proceeds from issuance of common stock	'	'	$19,700,000	'	'	'	'	'	'

STOCKHOLDERS_EQUITY_Reverse_St

STOCKHOLDERS' EQUITY - Reverse Stock Split - Additional Information (Details) (USD $)	0 Months Ended
	Jun. 09, 2014	Sep. 30, 2014	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'	'	'
Reverse stock split ratio	3.5	'	'
Total number of authorized shares	225,000,000	'	'
Common stock, shares authorized	125,000,000	125,000,000	125,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000	100,000,000
Preferred stock, par value (in dollars per share)	$0.00	$0.00	$0.00

STOCKHOLDERS_EQUITY_Initial_Pu

STOCKHOLDERS' EQUITY - Initial Public Offering and Concurrent Private Placements - Additional Information (Details) (USD $)	9 Months Ended	0 Months Ended
	Sep. 30, 2014	Jul. 07, 2014	Jul. 07, 2014	Jul. 07, 2014	Jul. 07, 2014	Jul. 29, 2014
		Common Stock Purchase Agreement	IPO	Private Placement	Private Placement	Over-Allotment Option
					Common Stock Purchase Agreement
Stockholder's Equity	'	'	'	'	'	'
Sale of common stock (in shares)	'	3,284,353	5,454,545	666,666	3,284,353	160,993
Share price (in dollars per share)	'	'	$6	$6	'	$6
Aggregate proceeds from sale of common stock	'	'	$32,700,000	$4,000,000	'	'
Net proceeds from sale of common stock	'	19,700,000	28,200,000	3,700,000	19,700,000	'
Stock issuance expenses	$3,129,584	'	$3,100,000	'	'	'

STOCKHOLDERS_EQUITY_Common_Sto

STOCKHOLDERS' EQUITY - Common Stock Issued for Nonrecourse Notes - Additional Information (Details)

3 Months Ended

9 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Jul. 07, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2014

Sep. 30, 2014

Mar. 31, 2014

Apr. 26, 2012

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

USD ($)

USD ($)

Common Stock

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Nonrecourse Note

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Sonkei

Sonkei

USD ($)

EUR (€)

Stockholder's Equity

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of common stock (in shares)

'

'

'

'

'

'

9,566,557

'

'

821,429

'

27,925

'

27,925

821,429

1,112,500

1,112,500

Face value

'

'

'

'

'

'

'

'

$4,700,000

$3,058,026

$4,700,000

$97,737

'

$97,737

'

$1,500,000

€ 1,119,017

Share price (in dollars per share)

'

'

'

'

'

'

'

'

$13.51

$3.71

$13.51

'

'

'

'

'

'

Interest rate (as a percent)

'

'

8.00%

'

'

'

'

'

'

0.19%

'

'

'

'

'

0.19%

0.19%

Number of shares remitted

'

'

'

'

'

'

'

'

348,926

'

'

'

348,926

'

'

'

'

Number of stock options (in shares)

2,621,910

2,621,910

'

646,759

0

'

'

'

1,300,000

'

1,300,000

'

'

'

'

'

'

Exercise price of stock options

'

'

'

'

'

'

'

'

4,700,000

'

'

'

'

'

'

'

'

Number of non-vested stock upon conversion of stock option (in shares)

'

'

'

'

'

0

'

'

926,604

'

926,604

1,275,530

'

1,275,530

821,429

'

'

Exercise price of non-vested stock

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

Stock based compensation expense

$300,000

$300,000

'

'

'

'

'

$10,500,000

'

'

'

'

'

'

'

'

'

STOCKHOLDERS_EQUITY_Common_Sha

STOCKHOLDERS' EQUITY - Common Shares Issued in Exchange for Nonrecourse Notes (Details)	Sep. 30, 2014	Dec. 31, 2011	Sep. 30, 2014	Nov. 12, 2013	Mar. 31, 2014	Apr. 26, 2012	Dec. 31, 2013	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
			Common Stock	Common Stock	Common Stock	Common Stock	Common Stock	Common Stock	Common Stock	Common Stock	Common Stock
				Sonkei	Nonrecourse Note	Nonrecourse Note	Nonrecourse Note	Nonrecourse Note	Nonrecourse Note	Nonrecourse Note	Nonrecourse Note
											Sonkei
Stockholder's Equity	'	'	'	'	'	'	'	'	'	'	'
Outstanding at the beginning of the period (in shares)	'	0	'	'	'	'	'	1,275,530	821,429	'	'
Sale of common stock (in shares)	'	'	9,566,557	'	'	821,429	27,925	'	27,925	821,429	1,112,500
Assumed in Sonkei merger	'	'	1,481,583	1,997,192	'	'	'	'	'	'	426,176
Number of shares remitted	'	'	'	'	-348,926	'	'	-348,926	'	'	'
Outstanding at the end of the period (in shares)	'	0	'	'	926,604	'	1,275,530	'	1,275,530	821,429	'
Shares vested at the end of the period (in shares)	926,604	'	'	'	'	'	'	'	'	'	'

STOCK_OPTION_PLAN_Additional_I

STOCK OPTION PLAN - Additional Information (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

6 Months Ended

9 Months Ended

6 Months Ended

9 Months Ended

6 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, except Share data, unless otherwise specified

Jul. 07, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

1-May-14

Jul. 07, 2014

Jul. 07, 2014

Sep. 30, 2014

Jul. 07, 2014

Jul. 07, 2014

Sep. 30, 2014

Apr. 30, 2014

Dec. 20, 2013

Apr. 30, 2014

Dec. 20, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 20, 2013

Dec. 20, 2013

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Employment Contract

Vest Over Four Year

Vest Over Three Year

Employees And Directors

Minimum

Maximum

Stock Option

2013 Equity Incentive Plan

2013 Equity Incentive Plan

2013 Equity Incentive Plan

2013 Equity Incentive Plan

2013 Equity Incentive Plan

2013 Equity Incentive Plan

2013 Equity Incentive Plan

2013 Equity Incentive Plan

2013 Equity Incentive Plan

Amended And Restated Equity Incentive Plan

Amended And Restated Equity Incentive Plan

Amended And Restated Equity Incentive Plan

Amended And Restated Equity Incentive Plan

Amended And Restated Equity Incentive Plan

Amended And Restated Equity Incentive Plan

Amended And Restated Equity Incentive Plan

Amended And Restated Equity Incentive Plan

item

Award Vested Over Four Year Beginning from November 12 2013

Awards Fully Vested and Exercisable upon Effective Date of IPO Registration

Stock Option

Stock Option

Stock Option

Stock Option

Stock Option

Stock Option

Stock Option

Award Vested on Grant Date

Award Vested Over Four Year Beginning from November 12 2013

Stock Option

Stock Option

Stock Option

Stock Option

Employment Contract

Awards Fully Vested and Exercisable upon Effective Date of IPO Registration

Minimum

Maximum

Award Vested Over Four Year Beginning from November 12 2013

Award Vested Over Four Year Beginning from November 12 2013

item

Stock Option Plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock reserved for issuance

'

'

'

'

'

'

'

'

'

'

'

3,543,754

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of share-based award

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected term

'

'

'

'

'

'

'

'

'6 years

'6 years 3 months

'

'

'

'

'

'

'

'

'5 years 9 months 18 days

'10 years

'

'

'

'

'6 years 3 months

'

'

'6 years 3 months

Risk free interest rate, minimum (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rate, maximum (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

Volatility, minimum (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

102.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Volatility, maximum (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

107.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Dividend yield (as a percent)

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

0.00%

'

'

0.00%

Fair value of common stock on grant date (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$9.49

'

'

'

'

'

'

$5.81

'

'

$6

'

'

$6

Risk free interest rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.90%

'

'

1.90%

Volatility (as a percent)

113.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

113.00%

'

'

113.00%

Additional disclosure

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation expense

'

$0.30

$0.30

'

'

'

'

'

'

'

'

'

'

'

'

$0.30

$0.90

$0.10

'

'

$2.80

'

'

'

'

'

$0.30

$1.10

Number of agreements

'

'

'

'

2

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in dollars per share)

'

'

$6.05

$9.49

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6

'

'

'

'

'

'

'

Vesting period

'

'

'3 years

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

Expected term

'

'

'

'

'

'

'

'

'6 years

'6 years 3 months

'

'

'

'

'

'

'

'

'5 years 9 months 18 days

'10 years

'

'

'

'

'6 years 3 months

'

'

'6 years 3 months

Total unrecognized compensation costs related to non-vested awards (in dollars)

'

9.6

9.6

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period over which unrecognized compensation costs related to non-vested awards is expected to be recognized

'

'

'3 years 1 month 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average contractual term of the options outstanding

'

'

'9 years 7 months 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of outstanding stock options (in dollars)

'

$0.10

$0.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Granted (in shares)

480,103

'

1,975,151

646,759

'

352,590

127,513

'

'

'

'

'

20,089

'

'

'

'

'

'

'

'

'

539,116

955,932

'

'

'

'

Fair value of common stock on grant date (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$9.49

'

'

'

'

'

'

$5.81

'

'

$6

'

'

$6

STOCK_OPTION_PLAN_Stock_Option

STOCK OPTION PLAN - Stock Option Activity (Details) (USD $)	0 Months Ended	9 Months Ended	12 Months Ended
	Jul. 07, 2014	Sep. 30, 2014	Dec. 31, 2013
Stock Options	'	'	'
Outstanding at the beginning of period (in shares)	'	646,759	0
Granted (in shares)	480,103	1,975,151	646,759
Outstanding at the end of the period (in shares)	'	2,621,910	646,759
Exercisable at the end of the period (in shares)	'	633,996	'
Weighted-Average Exercise Price	'	'	'
Outstanding at the beginning of period (in dollars per share)	'	$9.49	$0
Granted (in dollars per share)	'	$6.05	$9.49
Outstanding at the end of the period (in dollars per share)	'	$6.90	$9.49
Exercisable at the end of the period (in dollars per share)	'	$6.33	'

INCOME_TAXES_Additional_Inform

INCOME TAXES - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
					Federal research and development	Federal	New jersey
Operating Loss Carryforwards [Line Items]	'	'	'	'	'	'	'
Provision for income taxes	$0	$0	$0	$0	'	'	'
Net operating losses	'	'	'	'	'	16,000,000	11,000,000
Federal research and development credits	'	'	'	'	$200,000	'	'

COMMITMENTS_Additional_Informa

COMMITMENTS - Additional Information (Details) (USD $)	1 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
	sqft
Commitments And Contingencies Disclosure [Abstract]	'
Area of office space	4,043
Estimated annual rent payable	$0.10
Lease term	'2 years

RELATED_PARTY_TRANSACTIONS_Add

RELATED PARTY TRANSACTIONS - Additional Information (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Investor	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Accounting and other services expenses per year	'	'	'	'	$60
Related party expenses	0	15	35	45	'
Certain stockholders	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Related party expenses	$0	$100	$300	$300	'